Immuneering (IMRX) Enterprise Value (2021 - 2026)

Immuneering's Enterprise Value history runs 7 years deep, the most recent figure standing at -$156.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 336.89% year-over-year to -$156.7 million; the TTM figure through Mar 2026 stood at -$156.7 million (down 336.89% YoY), while the FY2025 annual figure was -$172.8 million, down 378.16% from the prior year.
• Enterprise Value for Q1 2026 stood at -$156.7 million, up from -$172.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$26.4 million in Q2 2025, with the low at -$227.6 million in Q3 2025.
• The 5-year median for Enterprise Value is -$97.2 million (2023), against an average of -$100.5 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 57.81% in 2024, then slumped 378.16% in 2025.
• Immuneering's Enterprise Value stood at -$105.5 million in 2022, then rose by 18.82% to -$85.7 million in 2023, then soared by 57.81% to -$36.1 million in 2024, then plunged by 378.16% to -$172.8 million in 2025, then increased by 9.34% to -$156.7 million in 2026.
• Business Quant data shows IMRX's Enterprise Value at -$156.7 million in Q1 2026, -$172.8 million in Q4 2025, and -$227.6 million in Q3 2025.